A mathematical model of insulin resistance in Parkinson's disease

This paper introduces a mathematical model representing the biochemical interactions between insulin signaling and Parkinson's disease. The model can be used to examine the changes that occur over the course of the disease as well as identify which processes would be the most effective targets for treatment. The model is mathematized using biochemical systems theory (BST). It incorporates a treatment strategy that includes several experimental drugs along with current treatments. In the past, BST models of neurodegeneration have used power law analysis and simulation (PLAS) to model the system. This paper recommends the use of MATLAB instead. MATLAB allows for more flexibility in both the model itself and in data analysis. Previous BST analyses of neurodegeneration began treatment at disease onset. As shown in this model, the outcomes of delayed, realistic treatment and full treatment at disease onset are significantly different. The delayed treatment strategy is an important development in BST modeling of neurodegeneration. It emphasizes the importance of early diagnosis, and allows for a more accurate representation of disease and treatment interactions.

[1]  Jer-Ming Chang,et al.  1-α,25-Dihydroxyvitamin D3 regulates inducible nitric oxide synthase messenger RNA expression and nitric oxide release in macrophage-like RAW 264.7 cells , 2004 .

[2]  Hongjun Song,et al.  Accumulation of the Authentic Parkin Substrate Aminoacyl-tRNA Synthetase Cofactor, p38/JTV-1, Leads to Catecholaminergic Cell Death , 2005, The Journal of Neuroscience.

[3]  D. Latchman,et al.  HSP27 but not HSP70 has a potent protective effect against α‐synuclein‐induced cell death in mammalian neuronal cells , 2004, Journal of neurochemistry.

[4]  Randolph A. Coleman,et al.  A mathematical model of cell death in multiple sclerosis , 2011, Journal of Neuroscience Methods.

[5]  Jing Liu,et al.  Nitric Oxide Induces Cell Death by Regulating Anti-Apoptotic BCL-2 Family Members , 2009, PloS one.

[6]  Jer-Ming Chang,et al.  1-alpha,25-Dihydroxyvitamin D3 regulates inducible nitric oxide synthase messenger RNA expression and nitric oxide release in macrophage-like RAW 264.7 cells. , 2004, The Journal of laboratory and clinical medicine.

[7]  Domenico Consoli,et al.  Dementia is associated with Insulin Resistance in patients with Parkinson's Disease , 2012, Journal of the Neurological Sciences.

[8]  Peng Lei,et al.  Tau protein: relevance to Parkinson's disease. , 2010, The international journal of biochemistry & cell biology.

[9]  H. Kamata,et al.  N‐Acetylcysteine suppresses TNF‐induced NF‐κB activation through inhibition of IκB kinases , 2000, FEBS letters.

[10]  Y. Moon,et al.  Mitochondrial membrane depolarization and the selective death of dopaminergic neurons by rotenone: protective effect of coenzyme Q10 , 2005, Journal of neurochemistry.

[11]  Howard E. Gendelman,et al.  Selective inhibition of NF-κB activation prevents dopaminergic neuronal loss in a mouse model of Parkinson's disease , 2007, Proceedings of the National Academy of Sciences.

[12]  René Hen,et al.  Decreased nuclear β‐catenin, tau hyperphosphorylation and neurodegeneration in GSK‐3β conditional transgenic mice , 2001 .

[13]  E. Stachowiak,et al.  Vitamin D increases expression of the tyrosine hydroxylase gene in adrenal medullary cells. , 1996, Brain research. Molecular brain research.

[14]  Manuel B. Graeber,et al.  PGC-1α, A Potential Therapeutic Target for Early Intervention in Parkinson’s Disease , 2010, Science Translational Medicine.

[15]  K. Jellinger,et al.  Neuropathological staging of Alzheimer lesions and intellectual status in Alzheimer's and Parkinson's disease patients , 1993, Neuroscience Letters.

[16]  Robert L. Green,et al.  A pragmatic approach to biochemical systems theory applied to an α-synuclein-based model of Parkinson's disease , 2009, Journal of Neuroscience Methods.

[17]  Eric Fontaine,et al.  Mitochondrial permeability transition pore inhibitors prevent ethanol-induced neuronal death in mice. , 2013, Chemical research in toxicology.

[18]  Michael Berk,et al.  The chemistry and biological activities of N-acetylcysteine. , 2013, Biochimica et biophysica acta.

[19]  Christopher K. Glass,et al.  The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation , 1998, Nature.

[20]  J. Kim,et al.  Insulin resistance impairs nigrostriatal dopamine function , 2011, Experimental Neurology.

[21]  W. Cefalu,et al.  Butyrate Improves Insulin Sensitivity and Increases Energy Expenditure in Mice , 2009, Diabetes.

[22]  F. Leighton,et al.  Oxidative stress and upregulation of mitochondrial biogenesis genes in mitochondrial DNA-depleted HeLa cells. , 1999, Biochemical and biophysical research communications.

[23]  V. Vasiliou,et al.  Neurotoxicity and Metabolism of the Catecholamine-Derived 3,4-Dihydroxyphenylacetaldehyde and 3,4-Dihydroxyphenylglycolaldehyde: The Role of Aldehyde Dehydrogenase , 2007, Pharmacological Reviews.

[24]  Youngmi Kim Pak,et al.  Overexpression of TFAM, NRF-1 and myr-AKT protects the MPP(+)-induced mitochondrial dysfunctions in neuronal cells. , 2012, Biochimica et biophysica acta.

[25]  Yeliz Guven,et al.  ORIGINAL ARTICLE , 2010 .

[26]  Fred H. Gage,et al.  Mechanisms Underlying Inflammation in Neurodegeneration , 2010, Cell.

[27]  Won-Seok Choi,et al.  Phosphorylation of p38 MAPK Induced by Oxidative Stress Is Linked to Activation of Both Caspase-8- and -9-mediated Apoptotic Pathways in Dopaminergic Neurons* , 2004, Journal of Biological Chemistry.

[28]  A. Gupte,et al.  Measures of striatal insulin resistance in a 6-hydroxydopamine model of Parkinson's disease , 2008, Brain Research.

[29]  S-H Hu,et al.  Pioglitazone ameliorates intracerebral insulin resistance and tau-protein hyperphosphorylation in rats with type 2 diabetes. , 2013, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.

[30]  Sean D. Hooper,et al.  Genome Analysis of the Anaerobic Thermohalophilic Bacterium Halothermothrix orenii , 2009, PloS one.

[31]  Michael Berk,et al.  N-acetylcysteine in psychiatry: current therapeutic evidence and potential mechanisms of action. , 2011, Journal of psychiatry & neuroscience : JPN.

[32]  TylerZARUBIN,et al.  Activation and signaling of the p38 MAP kinase pathway , 2005 .

[33]  Sang Hoon Joo,et al.  PKCδ promotes etoposide-induced cell death by phosphorylating Hsp27 in HeLa cells. , 2012, Biochemical and biophysical research communications.

[34]  J S Beckman,et al.  Pathological implications of nitric oxide, superoxide and peroxynitrite formation. , 1993, Biochemical Society transactions.

[35]  Hiroshi Kimura,et al.  Insulin receptor mRNA in the substantia nigra in Parkinson's disease , 1996, Neuroscience Letters.

[36]  Joseph L Evans,et al.  Oxidative stress and stress-activated signaling pathways: a unifying hypothesis of type 2 diabetes. , 2002, Endocrine reviews.

[37]  Kazuko Aoto,et al.  Cellular co-localization of phosphorylated tau- and NACP/α-synuclein-epitopes in Lewy bodies in sporadic Parkinson's disease and in dementia with Lewy bodies , 1999, Brain Research.

[38]  Mei Liu,et al.  Neuroprotection with pioglitazone against LPS insult on dopaminergic neurons may be associated with its inhibition of NF-κB and JNK activation and suppression of COX-2 activity , 2007, Journal of Neuroimmunology.

[39]  Tao Wang,et al.  Edaravone Guards Dopamine Neurons in a Rotenone Model for Parkinson's Disease , 2011, PloS one.

[40]  Bo Bai,et al.  Edaravone protected PC12 cells against MPP(+)-cytoxicity via inhibiting oxidative stress and up-regulating heme oxygenase-1 expression , 2014, Journal of the Neurological Sciences.

[41]  K. Heidenreich,et al.  Inhibition of p38 Mitogen-activated Protein Kinase by Insulin in Cultured Fetal Neurons (*) , 1996, The Journal of Biological Chemistry.

[42]  J. Cazareth,et al.  Involvment of Cytosolic and Mitochondrial GSK-3β in Mitochondrial Dysfunction and Neuronal Cell Death of MPTP/MPP+-Treated Neurons , 2009, PloS one.

[43]  Kenneth S. Kosik,et al.  Binding of Tau to Heat Shock Protein 27 Leads to Decreased Concentration of Hyperphosphorylated Tau and Enhanced Cell Survival* , 2004, Journal of Biological Chemistry.

[44]  P. Mehlen,et al.  Human hsp27, Drosophila hsp27 and human alphaB‐crystallin expression‐mediated increase in glutathione is essential for the protective activity of these proteins against TNFalpha‐induced cell death. , 1996, The EMBO journal.

[45]  Wei Zhang,et al.  Neuroprotective effects of edaravone on cognitive deficit, oxidative stress and tau hyperphosphorylation induced by intracerebroventricular streptozotocin in rats. , 2013, Neurotoxicology.

[46]  Ruedi Aebersold,et al.  Molecular characterization of mitochondrial apoptosis-inducing factor , 1999, Nature.

[47]  Michael R. Duchen,et al.  PINK1-Associated Parkinson's Disease Is Caused by Neuronal Vulnerability to Calcium-Induced Cell Death , 2009, Molecular cell.

[48]  Petteri Piepponen,et al.  Transgenic expression and activation of PGC-1α protect dopaminergic neurons in the MPTP mouse model of Parkinson’s disease , 2011, Cellular and Molecular Life Sciences.

[49]  Y. Agid,et al.  Nitric oxide synthase and neuronal vulnerability in parkinson's disease , 1996, Neuroscience.

[50]  K. Schulze-Osthoff,et al.  Small Stress Proteins as Novel Regulators of Apoptosis , 1996, The Journal of Biological Chemistry.

[51]  K. Winklhofer,et al.  Inactivation of Parkin by Oxidative Stress and C-terminal Truncations , 2003, Journal of Biological Chemistry.

[52]  Darlene R Goldstein,et al.  MAP Kinase Phosphatase 1 (MKP-1/DUSP1) Is Neuroprotective in Huntington's Disease via Additive Effects of JNK and p38 Inhibition , 2013, The Journal of Neuroscience.

[53]  Randolph A. Coleman,et al.  In silico evidence for glutathione- and iron-related pathogeneses in Parkinson's disease , 2010, Journal of Neuroscience Methods.

[54]  Piu Chan,et al.  α-Synuclein and dopamine metabolism , 2007, Molecular Neurobiology.